Skip to main content
. 2014 May 20;7:191–201. doi: 10.2147/IJNRD.S65158

Figure 6.

Figure 6

Total cost and cost reduction (USD) as a function of correlation between ESA and IV iron.

Note: For the cost-reduction model, it was assumed that ferric citrate reduced ESA usage by 20% and IV iron usage by 40%.

Abbreviations: ESA, erythropoietin-stimulating agent; IV, intravenous; q1, 25th percentile, q3, 75th percentile.